HealthLynked (HLYK) AI Stock Analysis

• Market Cap: $8.36M
• Dividend Yield: N/A
• Average Volume (3M): 97.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: -44.11%
• EPS Growth: -45.07%
• Country: US
• Employees: 20
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Care Facilities
• EPS (TTM): -0.02
• Shares Outstanding: 281,947,140
• 10 Day Avg. Volume: 71,604
• 30 Day Avg. Volume: 97,700
• PEG Ratio: -0.26
• Price to Book (P/B): -2.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.72
• Enterprise Value/Market Cap: 1.58
• Enterprise Value/Revenue: 1.00
• Enterprise Value/Gross Profit: 6.06
• Enterprise Value/Ebitda: -0.81
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: $0.00 ▼(-100.00%Downside)

The overall stock score is primarily driven by poor financial performance, reflecting significant risks and instability. Technical analysis provides some positive signals but is overshadowed by the negative financial outlook. Valuation remains unattractive due to persistent losses and lack of dividends.

HealthLynked Business Overview & Revenue Model

Company Description

HealthLynked (HLYK) is a healthcare technology company that operates within the digital health sector. The company focuses on improving healthcare by leveraging technology to connect patients, doctors, and medical data through its cloud-based platform. HealthLynked offers services such as patient appointment scheduling, medical record management, and telemedicine solutions, aimed at enhancing efficiency and accessibility in healthcare delivery.

How the Company Makes Money

HealthLynked generates revenue primarily through subscription fees for its platform services, which are charged to healthcare providers and facilities using their systems for patient management and engagement. The company also earns income from its telemedicine services, where patients pay for virtual consultations. Additionally, HealthLynked may derive revenue from partnerships with healthcare organizations and technology integrations that expand its service offerings and user base. Advertising and data analytics services offered to third parties could represent additional revenue streams, though specific details about these are not available.

HealthLynked Financial Statement Overview

Summary

HealthLynked is facing severe financial distress, with declining revenues, high net losses, and negative equity. The company shows a significant reliance on external financing and consistently negative cash flows, indicating urgent need for financial stabilization.

Income Statement

The income statement shows declining revenues from $9,197,992 in 2021 to $3,008,361 in 2024, indicating significant revenue contraction. Gross profit margins remained relatively high, but the company experienced substantial net losses, increasing from -$1,012,203 in 2023 to -$6,131,479 in 2024. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges and negative earnings before interest and taxes.

Balance Sheet

The balance sheet reveals a negative stockholders' equity of -$3,129,209 in 2024, down from $804,730 in 2023, highlighting financial instability. The debt-to-equity ratio is effectively unmeasurable due to negative equity, suggesting high leverage. The equity ratio is negative, indicating liabilities exceed assets, signaling potential insolvency risks.

Cash Flow

Cash flow analysis shows consistently negative free cash flow, with -$3,494,122 in 2024. Operating cash flow is negative, indicating the company is not generating sufficient cash from operations to cover its expenses. There is a slight improvement in financing cash flow, suggesting reliance on external financing to sustain operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.01M	5.72M	5.86M	9.20M	6.13M
Gross Profit	2.91M	2.35M	5.40M	6.18M	4.97M
EBITDA	-4.36M	-2.75M	-7.05M	-9.85M	-4.73M
Net Income	-6.13M	-1.01M	-8.82M	-10.41M	-6.15M
Balance Sheet
Total Assets	2.22M	4.28M	4.58M	10.69M	8.03M
Cash, Cash Equivalents and Short-Term Investments	76.24K	247.22K	61.89K	3.29M	162.18K
Total Debt	997.85K	1.97M	1.28M	978.19K	2.89M
Total Liabilities	5.35M	3.48M	4.27M	3.49M	6.68M
Stockholders Equity	-3.13M	804.73K	314.45K	7.20M	1.35M
Cash Flow
Free Cash Flow	-3.50M	-4.15M	-4.39M	-3.79M	-2.14M
Operating Cash Flow	-3.49M	-4.14M	-4.36M	-3.77M	-2.12M
Investing Cash Flow	422.40K	3.51M	-544.75K	-341.36K	1.81M
Financing Cash Flow	2.90M	824.09K	1.68M	7.24M	356.80K

HealthLynked Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HLYK, the sentiment is Positive. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.78 is Neutral, neither overbought nor oversold. The STOCH value of 56.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HLYK.

HealthLynked Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	67 Neutral	$21.94M	―	-25.29%	―	26.67%	44.02%
Sector *	52 Neutral	$7.34B	-0.07	-63.86%	2.34%	16.17%	0.23%
BMRA	49 Neutral	$8.66M	―	-72.70%	―	5.05%	26.13%
HLYK	47 Neutral	$8.36M	―	320.09%	―	-44.11%	-45.07%
MSPR	39 Underperform	$8.46M	―	-458.99%	―	34.74%	-53.67%
POAI	38 Underperform	$7.53M	―	-504.16%	―	-31.31%	49.27%
TSBX	34 Underperform	$8.33M	―	-126.03%	―	-100.00%	-27.44%

HealthLynked Corporate Events

HealthLynked Appoints New CFO Amid Leadership Changes

HealthLynked Corp. announced the appointment of Jeremy Daniel as its new Chief Financial Officer, effective January 15, 2025, following the resignation of David Rosal. Jeremy Daniel, with over two decades of experience in financial management and strategic planning across diverse industries, is expected to strengthen HealthLynked’s executive leadership and drive the company’s financial strategy, growth, and operational efficiency.